Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Longeveron Inc (LGVNR)

Longeveron Inc (LGVNR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease GlobeNewswire - Mon Jul 13, 6:05AM CDT

Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “ Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Appoints Marie Washburn as Chief Financial Officer GlobeNewswire - Mon Jul 6, 3:05PM CDT

Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectors Corporate focus on delivering top-line results from the Phase 2b clinical trial evaluating...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) GlobeNewswire - Thu Jun 18, 8:20AM CDT

MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) GlobeNewswire - Tue Jun 9, 8:20AM CDT

MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Present at BIO International Convention 2026 GlobeNewswire - Thu Jun 4, 8:15AM CDT

Company will highlight new and recently published data for stem cell therapy laromsestrocel Focus on potential partnership and strategic opportunities for Hypoplastic Left Heart Syndrome, Alzheimer’s...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities GlobeNewswire - Wed May 20, 3:05PM CDT

MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update GlobeNewswire - Wed May 13, 3:05PM CDT

On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS) GlobeNewswire - Mon May 11, 8:10AM CDT

Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment,...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) GlobeNewswire - Fri May 8, 3:05PM CDT

MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026 GlobeNewswire - Tue May 5, 3:15PM CDT

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.6220 (+1.40%)
LGVNR : 0.0005 (-37.50%)

Barchart Exclusives

Alphabet Is Up 94% and Meta Is Down 5%. Barchart Data Helps Pick the Best AI Dividend Stock to Buy Now. Barchart - Fri Jul 17, 6:00PM CDT
Alphabet’s broader ecosystem gives it the long-term edge, while Meta offers faster growth, a lower valuation and a higher yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.